Trials / Completed
CompletedNCT01242696
TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS® Element™ Coronary Stent System in Unselected Patients in Routine Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,014 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The goal of the TAXUS™ Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study is to evaluate real world clinical outcomes data for the TAXUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice.
Detailed description
A prospective, open label, multi-center observational study with an all-comers enrollment approach of approximately 1000 subjects at up to 50 sites in Europe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Coronary artery stenting | Coronary artery stenting with drug eluting stents |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2013-03-01
- Completion
- 2015-07-01
- First posted
- 2010-11-17
- Last updated
- 2017-02-03
Locations
37 sites across 10 countries: Belgium, France, Germany, Hungary, Ireland, Italy, Latvia, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01242696. Inclusion in this directory is not an endorsement.